Kidney Disease, Chronic Clinical Trial
Official title:
Randomised, Double-blind, Placebo-controlled and Parallel Dose Group Trial to Investigate Efficacy and Safety of Multiple Doses of Oral BI 690517 Over 14 Weeks, Alone and in Combination With Empagliflozin, in Patients With Diabetic and Non-diabetic Chronic Kidney Disease
This study is open to adults with chronic kidney disease. People with and without type 2 diabetes can take part in this study. The purpose of this study is to find out whether a medicine called BI 690517 improves kidney function in people with chronic kidney disease when taken alone or in combination with a medicine called empagliflozin. In the first part of the study, participants take empagliflozin or placebo as tablets every day for 2 months. Placebo tablets look like empagliflozin tablets but do not contain any medicine. In the second part, participants are divided into several groups. Depending on the group, the participants then additionally take different doses of BI 690517 or placebo as tablets for 3.5 months. In this case, placebo tablets look like BI 690517 tablets but do not contain any medicine. Participants are in the study for about 6 months. During this time, they visit the study site about 12 times. Where possible, about 4 of the 12 visits can be done at the participant's home instead of the study site. The trial staff may also contact the participants by phone or video call. Participants collect urine samples at home. These samples are then analysed to assess kidney function. At the end of the trial the results are compared between the different groups. The doctors also regularly check participants' health and take note of any unwanted effects.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03907657 -
Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau
|
Phase 2 | |
Not yet recruiting |
NCT06223750 -
Virtual Kidney Check and Follow-up
|
N/A | |
Completed |
NCT02468401 -
Prevention of Contrast Induced Nephropathy in Patients With Advanced Renal Dysfunction Undergoing Coronary Interventions
|
N/A | |
Completed |
NCT02238067 -
Survey on Anemia Therapy in Patients With Chronic Kidney Disease Not on Dialysis
|
N/A | |
Completed |
NCT01194154 -
A Study of Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in Participants With Chronic Kidney Disease (PRIMAVERA)
|
Phase 2 | |
Completed |
NCT02263833 -
An Observational, Prospective, Safety Study of Mircera (Monopegylated Epoetin Beta) in Clinical Practice
|
N/A | |
Active, not recruiting |
NCT04078750 -
PLATO - Medication Adherence in Transplant Recipients
|
N/A | |
Recruiting |
NCT05490511 -
Drug-gene-nutraceutical Interactions of Cannabidiol and Tacrolimus
|
Phase 1 | |
Terminated |
NCT05747053 -
Personalization of Immunosuppressive Treatment for Organ Transplant Recipients
|
||
Completed |
NCT03189212 -
Feasibility Study of Telemedicine for Dialysis Patients Awaiting Transplantation
|
N/A | |
Enrolling by invitation |
NCT05374291 -
The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD
|
Phase 3 | |
Recruiting |
NCT05033054 -
Effect of SGLT2i on Cardiovascular Biomarkers in Patients With Type 2 Diabetes and CKD Stage 3b-4
|
||
Completed |
NCT05064267 -
Hemostatic Profiles in Pediatric CKD
|
||
Not yet recruiting |
NCT06069518 -
Continuous Glucose Monitoring in Patients With Diabetes on Peritoneal Dialysis
|
||
Not yet recruiting |
NCT03590067 -
Oral Findings in a Group of Egyptian Pediatric Patients at Endstage Renal Disease
|
||
Recruiting |
NCT04014127 -
Coronary Microvascular Dysfunction in Chronic Kidney Disease
|
||
Recruiting |
NCT04626323 -
Randomized Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease
|
Phase 2 | |
Not yet recruiting |
NCT05774392 -
An Observational Study of Patients With Chronic Kidney Disease
|
||
Not yet recruiting |
NCT06343727 -
A High Protein Egg White Pudding for People With Kidney Failure (HiPE KF)
|
N/A | |
Completed |
NCT04515797 -
QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir
|
Phase 4 |